Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Switching ART in a Virologically Suppressed Person With Suspected Underlying Resistance

Listen to Timothy J. Wilkin, MD, MPH, provide a case-based overview of switching antiretroviral therapy in a person with viral suppression on their current regimen who has a history of virologic failure with drug-resistance mutations.
Timothy J. Wilkin, MD, MPH
Released: October 20, 2022

In this episode, Timothy J. Wilkin, MD, MPH, provides a case-based overview of switching antiretroviral therapy in a patient with viral suppression on their current regimen who has a history of virologic failure with drug-resistance mutations. Key findings from 2 relevant studies—the SWITCHMRK trial and Study 380-4030—are reviewed. The case discussion also highlights several other challenges that can be encountered in the switch setting, including incomplete immune recovery, comorbidities, and gastrointestinal intolerability of some antiretroviral drugs.

Information on this Educational Activity

Faculty

Timothy J. Wilkin, MD, MPH

Professor of Medicine
Division of Infectious Diseases
Weill Medical College of Cornell University
New York, New York

Timothy J. Wilkin, MD, MPH: consultant: Merck; researcher: GlaxoSmithKline/ViiV Healthcare, Merck.

Program Medium

This program has been made available online.

Acknowledgements

Jointly provided by the Association of Nurses in AIDS Care and Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings